Education
About Us
Working with TipRanks
Follow Us
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
PRLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $5.95
Previous CloseN/A
Volume107.75K
Average Volume (3M)139.27K
Market Cap
$50.43M
Enterprise Value$6.21M
Total Cash (Recent Filing)$73.22M
Total Debt (Recent Filing)$17.92M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 18, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding43,610,220
10 Day Avg. Volume174,110
30 Day Avg. Volume139,266
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.12
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$3.00Price Target Upside141.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPresentation of updated results from the Phase 1 trial evaluating PRT3789 in biomarker-selected SMARCA4-mutated cancers is expected to be a catalyst.
Financial PositionThe cash position of $133.6 million provides a strong financial foundation for Prelude Therapeutics.
Market PotentialPrelude Therapeutics shares represent a unique investment opportunity, with a potential upside of 646%.
Bears Say
Clinical RisksRisks include negative clinical results for PRT3789 and delays in advancing these candidates into registrational programs.
Competitive RisksThe competitive landscape poses risks, particularly with respect to other SMARCA2 inhibitors/degraders that are currently in clinical development.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $0.61 and its highest was $5.95 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $50.43M.
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 86 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.028.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 43,610,220 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went up 3.297%.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
Prelude Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (141.94% Upside)
$3.00 (141.94% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.81%
12-Months-Change
Fundamentals
Return on Equity
-96.33%
Trailing 12-Months
Asset Growth
-48.76%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$3.00
▲(141.94% Upside)
Technical Analysis
Spero Therapeutics
―
Iterum Therapeutics
―
Celularity
―
Repare Therapeutics
―
AN2 Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---